Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 23, 2011

KalVista Pharmaceuticals Launches with £8M in Series A Funding

  • KalVista Pharmaceuticals, which focuses on diabetic macular edema (DME), raised £8 million in a series A round from Novo and SV Life Sciences. The company is developing novel, small molecule plasma kallikrein inhibitors.

    The firm’s pipeline is at the preclinical stage. It targets both intravitreal injection and oral administration routes. KalVista acquired these inhibitors plus all relevant intellectual property from Vantia Therapeutics.

    Plasma kallikrein is a circulating serine protease that represents an attractive drug target as it is believed to be central to the pathogenesis of DME within the diseased retina but is not essential for normal function. The detrimental effects of plasma kallikrein on the retina occur independently of VEGF, which has been an area of intense recent interest as a target for treating DME.

    However, while intravitreal VEGF inhibitors have shown clear benefit in clinical trials through reducing macular edema and increasing visual acuity, a large proportion of DME patients do not respond fully to VEGF treatment, according to KalVista.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »